Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Lancet HIV. 2022 Jun;9(6):e394-e403. doi: 10.1016/S2352-3018(22)00037-6. Epub 2022 Apr 27.
We report the long-term impact of ART in women of reproductive age (15-49 years) in Africa who have been using ART for up to 10 years. We assess outcomes of retention, adherence, maternal health, fertility intentions, and safety.
This longitudinal, multicountry study (PROMOTE) enrolled women who initiated ART in an earlier perinatal clinical trial, PROMISE. PROMISE occurred from 2011 to 2016 and PROMOTE follow-up started in 2016 and is ongoing. The PROMOTE study was done at eight sites in four countries: Malawi (Blantyre and Lilongwe), South Africa (Durban and Soweto), Uganda (Kampala), and Zimbabwe (Harare, Seke North, and St Mary's). After baseline enrolment, women and their children are followed up every 6 months to collect information on medical history, antiretroviral therapy (ART) use, adherence, and health information, and to do physical examinations and laboratory tests. Obesity was defined as a body-mass index of 30 kg/m or more. Data analyses were restricted to summaries of the main long-term outcomes (retention, adherence, maternal health, fertility intentions, and safety). We used descriptive and stratified analyses, and estimated rates using person-years of follow-up and computed probabilities based on Kaplan-Meier methods.
PROMOTE enrolled 1987 mothers and 2522 children. The median follow-up time for mothers was 41·8 (IQR 35·8-42·0) months and for children was 35·7 (23·8-42·0) months. Overall retention rates were 96·5% for mothers and 94·3% for children at 12 months, and, at 42 months, were 88·9% for mothers and 85·4% for children. 1115 (89·1%) of 1252 women had an undetectable viral load at 42 months, which varied by site (81·7-93·8%). Reported maternal health improved over time, with the proportion of women with excellent to very good health increasing from 67·5% at baseline to 87·5% at 42 months, the proportion of unwell participants who visited a health centre declining from 14·7% to 2·8%, and the proportion of those admitted to hospital declining from 1·5% to 1·0%. The desire to have more children was consistently high at some sites. The proportion of women with obesity was high in South Africa and increased over time from 40·2% at baseline to 52·8% at 42 months. The overall pregnancy rate was 17·6 (95% CI 16·5-18·7) per 100 women-years, and mortality rates were 2·4 (1·4-3·9) per 1000 person-years for mothers and 3·4 (2·2-5·10) per 1000 person-years for children (0-9 years).
The findings from this multicountry study are reassuring. These findings show that African women can consistently use ART for a long period after initiation, and long-term benefits can be maintained. Services to support maternal HIV care, treatment, and reproductive health should be strengthened.
US President's Emergency Plan for AIDS Relief.
我们报告了在非洲生育年龄段(15-49 岁)的妇女中使用抗逆转录病毒治疗(ART)长达 10 年的长期影响。我们评估了保留率、依从性、产妇健康、生育意愿和安全性。
这项纵向、多国研究(PROMOTE)纳入了在早期围产期临床试验 PROMISE 中开始接受 ART 的妇女。PROMISE 于 2011 年至 2016 年进行,而 PROMOTE 随访于 2016 年开始并正在进行中。PROMOTE 研究在四个国家的八个地点进行:马拉维(布兰太尔和利隆圭)、南非(德班和索韦托)、乌干达(坎帕拉)和津巴布韦(哈拉雷、塞克北部和圣玛丽)。基线入组后,每隔 6 个月对妇女及其子女进行随访,收集病史、抗逆转录病毒治疗(ART)使用、依从性和健康信息,并进行体格检查和实验室检查。肥胖定义为体重指数为 30kg/m 或以上。数据分析仅限于主要长期结局(保留率、依从性、产妇健康、生育意愿和安全性)的总结。我们使用描述性和分层分析,并根据随访的人年估计率,并根据 Kaplan-Meier 方法计算概率。
PROMOTE 招募了 1987 名母亲和 2522 名儿童。母亲的中位随访时间为 41.8(IQR 35.8-42.0)个月,儿童的中位随访时间为 35.7(23.8-42.0)个月。12 个月时,母亲和儿童的总体保留率分别为 96.5%和 94.3%,42 个月时,母亲的保留率为 88.9%,儿童的保留率为 85.4%。1115(89.1%)名 1252 名妇女在 42 个月时病毒载量无法检测,这因地点而异(81.7-93.8%)。报告的产妇健康状况随着时间的推移而改善,身体健康状况极好至非常好的妇女比例从基线时的 67.5%增加到 42 个月时的 87.5%,就诊于卫生中心的不适妇女比例从 14.7%下降到 2.8%,住院的妇女比例从 1.5%下降到 1.0%。一些地点的妇女想要更多孩子的愿望一直很高。南非妇女肥胖比例很高,从基线时的 40.2%增加到 42 个月时的 52.8%。总的妊娠率为 17.6(95%CI 16.5-18.7)每 100 名妇女年,母亲的死亡率为 2.4(1.4-3.9)每 1000 人年,儿童的死亡率为 3.4(2.2-5.10)每 1000 人年(0-9 岁)。
这项多国研究的结果令人欣慰。这些发现表明,非洲妇女可以在开始使用抗逆转录病毒治疗后持续使用很长一段时间,并且可以维持长期的益处。应加强支持艾滋病毒母婴护理、治疗和生殖健康的服务。
美国总统艾滋病紧急救援计划。